IP Group (LON:IPO) Releases Quarterly Earnings Results

IP Group (LON:IPO) posted its quarterly earnings results on Tuesday. The company reported GBX 3.53 earnings per share (EPS) for the quarter, Digital Look Earnings reports. IP Group had a net margin of 321.64% and a return on equity of 14.25%.

Here are the key takeaways from IP Group’s conference call:

• NAV per share rose 3.2% to 114p at June 30 and approximately 117p by September 11, while gross cash reached about £239 million. Portfolio companies also raised more than £500 million from third parties, providing external validation of their progress.
• Pfizer’s obesity programs continued to de-risk, with the royalty asset’s carrying value increasing by £27 million to roughly £153 million after the amylin combination entered Phase IIb. Berobenatide Phase III recruitment is reportedly close to completion, supporting a potential 2028 launch, although clinical, regulatory and commercial risks remain.
• Cash realizations were strong at £69 million in the first half and approximately £86 million year to date, taking cumulative proceeds since the start of 2025 to £154 million. Management remains confident in reaching its £250 million realization target by the end of 2027.
• Oxford Nanopore reported 12% constant-currency revenue growth, a 400-basis-point gross-margin improvement and an adjusted EBITDA loss that more than halved. It remains on track for EBIT break-even in 2027 and positive free cash flow in 2028, supported by a new cross-licensing agreement with $35 million of committed revenue plus royalties.
• Management acknowledged that the shares continue to trade at roughly a 40% discount to NAV and said reducing the gap will require sustained NAV growth, more realizations and shareholder-focused capital allocation. Around £50 million is available for potential shareholder returns, but the timing and form of any action have not been decided.

IP Group Stock Down 0.6%

Shares of LON IPO opened at GBX 68.40 on Thursday. The stock’s 50-day simple moving average is GBX 67.85 and its two-hundred day simple moving average is GBX 63.09. IP Group has a twelve month low of GBX 48 and a twelve month high of GBX 75. The firm has a market capitalization of £604.26 million, a P/E ratio of 9.63 and a beta of 1.27.

Insider Activity

In related news, insider Michael Queen bought 200,000 shares of the company’s stock in a transaction on Tuesday, August 4th. The stock was acquired at an average cost of GBX 66 per share, for a total transaction of £132,000. Also, insider David Baynes purchased 26,368 shares of the business’s stock in a transaction on Wednesday, August 5th. The stock was bought at an average cost of GBX 68 per share, with a total value of £17,930.24. In the last 90 days, insiders acquired 271,368 shares of company stock worth $18,053,024. 1.57% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

IPO has been the topic of several recent research reports. Berenberg Bank restated a “buy” rating and set a GBX 119 target price on shares of IP Group in a research report on Tuesday. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a GBX 110 price objective on shares of IP Group in a report on Wednesday. Two equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of GBX 114.50.

About IP Group

IP Group accelerates the impact of science for a better future. As the most active UK based, early-stage science investor, we develop and support some of the world’s most exciting businesses in deeptech, life sciences and cleantech (led by Kiko Ventures). Through Parkwalk, the UK’s largest growth EIS fund manager, we also back world-changing innovation emerging in leading universities and research institutions. Our specialist investment team combines sector expertise with an international approach.